Danaher Corporation (DHR)
Ciencias de la vida y diagnóstico
A quality portfolio in bioprocessing, life sciences, and diagnostics organized under the Danaher Business System, but with weighted organic growth of just ~2.1% in 2025, an acquisition engine that the annual report itself acknowledges has slowed, and real net debt that the bridge charges in full; at 40× on NOPAT, Overvalued with a -12% over 5 years.
- Price
- $215.69
- Intrinsic value (5y, base)
- $106
- Total annual return (5y)
- -12.0%
- Status (nominal)
- Overvalued
- Margin of safety
- No margin
The essentials
- Diversified portfolio in bioprocessing, life sciences, and diagnostics with ~59% of sales outside the U.S., unified by the Danaher Business System.
- Weighted organic growth of just ~2.1% in 2025 (Biotechnology +6.5%, Life Sciences −1.5%, Diagnostics +1.5%) and an acknowledged slowdown in the acquisition engine.
- Valued on EV/NOPAT (med-tech and diagnostics band [16,22]×, low end given the weak growth) with real net debt of ~$22.2 billion charged in the bridge; net buyback ~1.6%/year.
Intrinsic value — two valuation methods
Total return at 5 years: -12.0%/year = -13.2% appreciation + 1.3% dividend. The target price ($106) is ex-dividend; the $10 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $144 · Multiples $94) is below the market price ($216).
Pillars of the analysis
The verdict — today vs 5 years
Today — expensive, no margin of safety: at $216 trades ~130.3% above its value discounted to today (~$94); the expected return does not even reach the risk-free rate (4.5%).
At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.
The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$59.
Thesis
The business
Danaher is a quality portfolio in bioprocessing, life sciences, and diagnostics, unified by the Danaher Business System, a continuous-improvement system applied uniformly across more than 15 operating companies. Weighted organic growth of just ~2.1% in 2025 (Biotechnology +6.5% recovering, Life Sciences −1.5% hit by a $432 million brand impairment, Diagnostics +1.5% amid pricing pressure in China) and the acknowledged slowdown in the acquisition engine — the company's historical value-creation pillar — break with the compounding pattern that sustained the stock's premium multiple.
The valuation
It is valued on EV/NOPAT (the medical-devices-and-diagnostics archetype, band [16,22]×, translated from P/E because the adjusted-earnings reconciliation was not located in the 10-K sections reviewed), with a multiple at the low end of the band given the weak growth and a bridge that fully charges the company's real debt. At 40×, Overvalued with a -12% over 5 years versus the current price.
The margin of safety
No margin of safety: the price already discounts a demanding scenario. The current discount, if any, is not supported by an identifiable source of missing buyers or forced or emotional selling: the market continues to pay Danaher's historical quality premium despite the organic slowdown.
What to watch
The central disconfirming test is the pace of acquisitions: if it reactivates (with Masimo as the first test) and organic growth exceeds 4-5%, the stagnation thesis reverses; if it remains stalled, the current multiple is exposed to compression.
Educational / informational. Does not constitute investment advice.